ABIVAX (EPA:ABVX) | WebDisclosure

PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 8 months ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Abivax announces positive interim results of obefazimod in ulcerative colitis patients after 2 years, showing maintenance of remission and safety profile consistency

Abivax Obefazimod Ulcerative Colitis Safety Efficacy
PRESS RELEASE

published on 10/03/2024 at 08:30, 1 year 8 months ago

Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la tolérance d’obefazimod 25 mg chez des patients atteints de RCH modérée à sévère après deux ans de maintenance en ouvert
Abivax annonce des résultats positifs d'une analyse intermédiaire sur l'efficacité d'obefazimod 25 mg pour les patients atteints de RCH modérée à sévère après 2 ans de traitement

Abivax Obefazimod Efficacité Tolérance RCH Modérée
BRIEF

published on 09/26/2024 at 08:35, 1 year 8 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Obefazimod Ulcerative Colitis Phase 2b Study UEG Week 2024
BRIEF

published on 09/26/2024 at 08:35, 1 year 8 months ago

Abivax présentera trois résumés sur l'obéfazimod dans la rectocolite hémorragique lors de la semaine UEG 2024

Abivax Obefazimod Rectocolite Hémorragique Étude De Phase 2b Semaine UEG 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 8 months ago

Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024. Les présentations mettent en lumière l'efficacité et la sécurité du traitement

Abivax Obefazimod Phase 2b Rectocolite Hémorragique UEG Week
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 8 months ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Abivax to present Phase 2b trial results of obefazimod in ulcerative colitis at UEG Week 2024, showcasing efficacy and safety data for potential oral therapy

Abivax Obefazimod Ulcerative Colitis Clinical Trial UEG Week 2024
PRESS RELEASE

published on 09/26/2024 at 08:30, 1 year 8 months ago

Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024
Abivax annonce la présentation de trois abstracts sur Obefazimod dans la rectocolite hémorragique lors du congrès UEG Week 2024

Abivax Obefazimod Rectocolite Hémorragique Traitement UEG Week 2024
BRIEF

published on 09/25/2024 at 22:06, 1 year 8 months ago

Abivax Announces Ulcerative Colitis Combination Therapy Strategy and Preclinical Data

Obefazimod Ulcerative Colitis Preclinical Data Combination Therapy Etrasimod
BRIEF

published on 09/25/2024 at 22:06, 1 year 8 months ago

Abivax annonce sa stratégie de traitement combiné contre la rectocolite hémorragique et ses données précliniques

Obefazimod Rectocolite Hémorragique Données Précliniques Etrasimod Thérapie Combinée
PRESS RELEASE

published on 09/25/2024 at 22:01, 1 year 8 months ago

Abivax Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease Mouse Model
Abivax announces preclinical data of Obefazimod and Etrasimod combination therapy in IBD mouse model, aiming to break through efficacy ceiling in UC treatment. More updates expected in Q4 2024

Abivax Obefazimod Preclinical Data Etrasimod IBD Mouse Model

Published on 06/22/2026 at 15:58, 3 hours 21 minutes ago

Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Published on 06/22/2026 at 15:30, 3 hours 49 minutes ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Published on 06/22/2026 at 15:00, 4 hours 19 minutes ago

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Published on 06/22/2026 at 14:01, 5 hours 18 minutes ago

Worksport (NASDAQ:WKSP) Achieves 35% May Gross Margin, Lands Meyer Distribution, Targets $36M+ Revenue Run-Rate
Published on 06/22/2026 at 14:00, 5 hours 19 minutes ago

Adcore Enters Strategic Partnership with TikTok as a Channel Sales Partner

View all ACCESSWIRE

Published on 06/22/2026 at 18:54, 25 minutes ago

EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026
Published on 06/22/2026 at 18:30, 49 minutes ago

Amprion welcomes RWE’s entry into M31
Published on 06/22/2026 at 18:30, 49 minutes ago

Avolta awarded 10-year contract at Orlando International Airport across travel retail and F&B
Published on 06/22/2026 at 18:05, 1 hour 14 minutes ago

Bybit EU Strengthens European Positioning Ahead of MiCAR Transition
Published on 06/22/2026 at 18:00, 1 hour 19 minutes ago

Zendure Unveils the ZEN+ HOME AI Energy Ecosystem at Intersolar 2026

View all EQS

Published on 06/22/2026 at 18:45, 34 minutes ago

Governance evolution
Published on 06/22/2026 at 18:45, 34 minutes ago

ÉVOLUTION DE LA GOUVERNANCE
Published on 06/22/2026 at 18:16, 1 hour 2 minutes ago

ANTOINE FREY INCREASES HIS STAKE IN FREY
Published on 06/22/2026 at 18:16, 1 hour 2 minutes ago

ANTOINE FREY SE RENFORCE AU CAPITAL DE FREY
Published on 06/22/2026 at 18:00, 1 hour 19 minutes ago

GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION

View all LES ECHOS COMFI WIRE

News